[go: up one dir, main page]

WO2003030938A1 - Immunotherapeutics for cancer - Google Patents

Immunotherapeutics for cancer Download PDF

Info

Publication number
WO2003030938A1
WO2003030938A1 PCT/JP2002/010446 JP0210446W WO03030938A1 WO 2003030938 A1 WO2003030938 A1 WO 2003030938A1 JP 0210446 W JP0210446 W JP 0210446W WO 03030938 A1 WO03030938 A1 WO 03030938A1
Authority
WO
WIPO (PCT)
Prior art keywords
activating
cancer
tissue
inducing
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/010446
Other languages
French (fr)
Japanese (ja)
Inventor
Akikuni Yagita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORIENT CANCER THERARY CO Ltd
Original Assignee
ORIENT CANCER THERARY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ORIENT CANCER THERARY CO Ltd filed Critical ORIENT CANCER THERARY CO Ltd
Priority to JP2003533969A priority Critical patent/JPWO2003030938A1/en
Publication of WO2003030938A1 publication Critical patent/WO2003030938A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)

Abstract

It is intended to provide a novel means for a novel immunotherapy under paying attention to the effects of activating NK cells, activating NKT cells, inhibiting angiogenesis, inducing IL-12 production and inducing IFNϜ production. More specifically speaking, a novel use of immunotherapeutics for cancer characterized by comprising, to treat cancer depending on tissue and/or tissue type, classifying the treatment mechanisms at least into: (1) an effect of inhibiting angiogenesis; (2) an effect of inducing Th1 cytokines (TNFα, IFNϜ and IL-12) and activating CTL; (3) increasing NK cells or activating the same; and (4) increasing NKT cells or activating the same, then measuring markers corresponding to respective effects, analyzing the measurement data depending on cancer tissue and/or tissue type, and thus selecting a prescription appropriate for the cancer tissue and/or tissue type.
PCT/JP2002/010446 2001-10-09 2002-10-08 Immunotherapeutics for cancer Ceased WO2003030938A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003533969A JPWO2003030938A1 (en) 2001-10-09 2002-10-08 Cancer immunotherapy

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2001-312051 2001-10-09
JP2001312051 2001-10-09
JP2001341116 2001-11-06
JP2001-341116 2001-11-06
JP2002-62373 2002-03-07
JP2002062373 2002-03-07
JP2002139004 2002-05-14
JP2002-139004 2002-05-14

Publications (1)

Publication Number Publication Date
WO2003030938A1 true WO2003030938A1 (en) 2003-04-17

Family

ID=27482606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010446 Ceased WO2003030938A1 (en) 2001-10-09 2002-10-08 Immunotherapeutics for cancer

Country Status (2)

Country Link
JP (1) JPWO2003030938A1 (en)
WO (1) WO2003030938A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054497A1 (en) * 2003-12-02 2005-06-16 Orient Cancer Therapy Co., Ltd. Method of screening immunological therapeutic drug for cancer
WO2005071409A1 (en) * 2004-01-27 2005-08-04 Orient Cancer Therapy Co., Ltd. Remedy for pancreatic cancer
WO2005079813A1 (en) * 2004-02-19 2005-09-01 Kibun Food Chemifa Co., Ltd. Composition for nkt cell activation
WO2006038527A1 (en) * 2004-10-01 2006-04-13 Three B Co., Ltd. Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient
JP2011525795A (en) * 2008-05-29 2011-09-29 トランジェーヌ、ソシエテ、アノニム Biomarkers and related methods for patient selection
WO2011162419A1 (en) * 2010-06-25 2011-12-29 財団法人東京都医学総合研究所 Tumor growth controlling method targeting galactosylceramide expression factor-1
WO2017213249A1 (en) * 2016-06-09 2017-12-14 学校法人川崎学園 Method for testing natural killer cell functions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0844002A1 (en) * 1996-11-11 1998-05-27 Akikuni Yagita Use of activated hemicellulose for the induction of interleukin-12
JPH10147534A (en) * 1996-11-19 1998-06-02 Akikuni Yakida Tumor neovascular inhibitor and pharmaceutical composition
JP2001033460A (en) * 1999-07-22 2001-02-09 Kyokuho Yagita Early diagnostic method for progressive stomach cancer
JP2001048795A (en) * 2000-01-01 2001-02-20 Kyokuho Yagita Oral ingestion formulation with anti-tumor effect consisting of finely powdered shark cartilage
WO2001070251A1 (en) * 2000-03-24 2001-09-27 Orient Cancer Therapy Co., Ltd. Anticancer compositions
WO2001082935A1 (en) * 2000-04-28 2001-11-08 Orient Cancer Therapy Co.,Ltd. Remedies for cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0844002A1 (en) * 1996-11-11 1998-05-27 Akikuni Yagita Use of activated hemicellulose for the induction of interleukin-12
JPH10147534A (en) * 1996-11-19 1998-06-02 Akikuni Yakida Tumor neovascular inhibitor and pharmaceutical composition
JP2001033460A (en) * 1999-07-22 2001-02-09 Kyokuho Yagita Early diagnostic method for progressive stomach cancer
JP2001048795A (en) * 2000-01-01 2001-02-20 Kyokuho Yagita Oral ingestion formulation with anti-tumor effect consisting of finely powdered shark cartilage
WO2001070251A1 (en) * 2000-03-24 2001-09-27 Orient Cancer Therapy Co., Ltd. Anticancer compositions
WO2001082935A1 (en) * 2000-04-28 2001-11-08 Orient Cancer Therapy Co.,Ltd. Remedies for cancer

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
AKIKUNI YAGITA ET AL.: "Human natural (Hn) IL-12 inducer o mochiita shinmen'eki ryoho", BIOTHERAPY, vol. 13, no. 1, 1999, pages 124, XP002961326 *
AKIKUNI YAGITA ET AL.: "IL-12 yuki busshitsu no AHCC to kekkan shinsei sohaizai to o mochiita BRM ryoho no kisoteki rinshoteki kento", BIOTHERAPY, vol. 12, no. 1, 1998, pages 38, XP002961327 *
AKIKUNI YAGITA ET AL.: "Shinmen'eki ryoho (kasho) (nobel immunotherapy for cancer; NITC) ni okeru kekkan shinsei sogaizai no yakuwari", BIOTHERAPY, vol. 14, no. 10, 2000, pages 973 - 981, XP002961321 *
AKIKUNI YAGITA ET AL.: "Shinmen'eki ryoho (NITC) ni okeru NKT-saibo no yakuwari", BIOTHERAPY, vol. 15, no. 3, May 2001 (2001-05-01), pages 403, XP002961325 *
AKIKUNI YAGITA ET AL.: "Shinsei kekkan sogaizai to naiinsei IL-12 to o mochiita shinmen'eki ryoho - partuclarly, NKT saibo no kan'yo ni tsuite", BIOTHERAPY, vol. 14, no. 5, 2000, pages 433 - 439, XP002961319 *
AKIKUNI YUGITA ET AL.: "Natural IL-12 yukizai no kakushu shinkogan ni taisuru sayo", BIOTHERAPY, vol. 14, no. 1, 2000, pages 33 - 37, XP002961320 *
DATABASE EMBASE [online] accession no. STN Database accession no. 2000064223 *
DATABASE EMBASE [online] accession no. STN Database accession no. 2000064228 *
DATABASE EMBASE [online] accession no. STN Database accession no. 2000242817 *
DATABASE EMBASE [online] accession no. STN Database accession no. 2000242822 *
DATABASE EMBASE [online] accession no. STN Database accession no. 2000429146 *
SHOJI MARUYAMA ET AL.: "Shiko daichogan ni okeru shinmen'eki ryoho no yukosei", BIOTHERAPY, vol. 14, no. 5, 2000, pages 460 - 463, XP002961322 *
SHOJI MARUYAMA ET AL.: "Shinko daichogan ni okeru shinmen'eki ryoho no yukosei", BIOTHERAPY, vol. 14, no. 1, May 2001 (2001-05-01), pages 48 - 50, XP002961324 *
SHOJI MARUYAMA ET AL.: "Shinko igan ni okeru shinmen'eki ryoho no yukosei", BIOTHERAPY, no. 36, 1999, pages 59 - 62, XP002961323 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054497A1 (en) * 2003-12-02 2005-06-16 Orient Cancer Therapy Co., Ltd. Method of screening immunological therapeutic drug for cancer
WO2005071409A1 (en) * 2004-01-27 2005-08-04 Orient Cancer Therapy Co., Ltd. Remedy for pancreatic cancer
WO2005079813A1 (en) * 2004-02-19 2005-09-01 Kibun Food Chemifa Co., Ltd. Composition for nkt cell activation
WO2006038527A1 (en) * 2004-10-01 2006-04-13 Three B Co., Ltd. Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient
JP2011525795A (en) * 2008-05-29 2011-09-29 トランジェーヌ、ソシエテ、アノニム Biomarkers and related methods for patient selection
WO2011162419A1 (en) * 2010-06-25 2011-12-29 財団法人東京都医学総合研究所 Tumor growth controlling method targeting galactosylceramide expression factor-1
WO2017213249A1 (en) * 2016-06-09 2017-12-14 学校法人川崎学園 Method for testing natural killer cell functions

Also Published As

Publication number Publication date
JPWO2003030938A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
NO20002121L (en) Benzothiazol-protein-tyrosine kinase inhibitors
DK1992695T3 (en) Lectin transmembrane antigen of type C expressed in human prostate cancer and disorders thereof
GB0127916D0 (en) Method
ATE437623T1 (en) DEVICE FOR RAISING PATIENTS IN A BED
NO20052760D0 (en) Process for the treatment of cancer and related methods.
WO2000044774A3 (en) Inhibition of stat3 signal transduction for human cancer therapy
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
AU2002341359A1 (en) Apparatus and method for cryosurgical treatment of tumors of the breast
AU2003285926A8 (en) Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2003030938A1 (en) Immunotherapeutics for cancer
AU2003273176A1 (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
AU2002252444A1 (en) Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
PL342184A1 (en) Derivatives of hydroxamic and carboxylic acids
AU2003303374A1 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
NO20050428L (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and their use in the treatment of benign and malignant tumor diseases
CA2051418A1 (en) Novel vitamin d analogues
WO2001032210A3 (en) Compositions for treating atheroma and neoplastic tissue
AU2001286398A1 (en) Apparatus for determining the position of radioactive seeds in needles used for radioactive seed therapy for prostate cancer
WO2002064023A3 (en) Fra-1 expression in brain cancer
BRPI0409155A (en) high acid maintenance citric juice resin deacidification
DK1763858T3 (en) Lighting equipment with integrated warning and data collection equipment
FR2861951B1 (en) GRINDING MACHINE COMPRISING AN ADJUSTING DEVICE FOR LIMITING THE DEBATMENT OF THE ENTIRE SOCS DOWN
WO2002025286A3 (en) Methods for the diagnosis of neoplastic disorders using angiogenin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003533969

Country of ref document: JP

122 Ep: pct application non-entry in european phase